iSOFT Hosts Forum to Discuss Future Role of eClinical Trial Technologies

iSOFTiSOFT recently hosted the eClinical Forum to discuss how existing and emerging healthcare environments impact on clinical trials, and the future role of eClinical trial technologies.

The eClinical Forum was formed in 2000 by Pharmaceutical industry representatives with a vision to create a non-commercial and informal environment in which to network with peers, share ideas and experiences, and to shape the future of the clinical research environment.

The meeting was held at iSOFT's headquarters and was opened by iSOFT chief executive Andrea Fiumicelli who explained that despite the enormous progresses made, much needed to be done to improve the delivery of healthcare, and in particular improve safety through better use of information systems.

The clinical trial process was a key focus of the session. Identifying eligible patients for clinical trials is a constant challenge, and 58 per cent of clinical trials fail to achieve their recruitment targets. Dr Joerg Kraenzlein, director of life science at iSOFT described a system which is being developed to help investigators and pharmaceuticals companies conduct clinical trials more easily. "We want to build a network for physicians to collaborate, foster the use of personalised medicine and the production of clinical trials helping to speed up the process," he explained.

In the iSOFT system under development, patient records are de-identified and medical terms extracted to create the AccelCDB (Clinical Database). The investigator can then use the AccelFind web base application to identify suitable patients for the trial by defining the inclusion and exclusion criteria.

"It just takes 5 to 10 seconds to screen 10,000 medical records, whereas with a manual process a physician has to work for weeks," Dr Kraenzlein said.

The forum agreed that there is an urgent need for an integrated solution for research activities to increase efficiency while maintaining a high level of quality. This will help shorten the clinical trial process and ultimately assist in bringing drugs to market in a more timely way.

Related news articles:

About iSOFT a CSC company
Headquartered in Banbury, UK, iSOFT is one of the world's largest healthcare IT companies serving 13,000 healthcare providers in over 40 countries across five continents. Its software product portfolio is one of the most extensive available, covering every aspect of healthcare delivery and planning. These include interoperable e-health solutions that build on existing systems to maximize current investments.

iSOFT's business is driven by the collective talent, experience and commitment of over 3,000 specialists in 19 countries. Through a global network of subsidiaries and extensive partner network, iSOFT also has substantial experience of national healthcare sectors and expert knowledge of local market needs.

iSOFT is a CSC Company.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...